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Interfacial hydrophobicityThere are many peptides known that inhibit the entry of enveloped viruses into cells, including one peptide that
is successfully being used in the clinic as a drug. In this review, we discuss the discovery, antiviral activity and
mechanism of action of such peptides. While peptide entry inhibitors have been discovered by a wide variety
of approaches (structure-based, accidental, intentional, rational and brute force) we show here that they share
a common physical chemical property: they are at least somewhat hydrophobic and/or amphipathic and have
a propensity to interact with membrane interfaces. We propose that this propensity drives a shared mechanism
of action for many peptide entry inhibitors, involving direct interactions with viral and cellular membranes, as
well as interactions with the complex hydrophobic protein/lipid interfaces that are exposed, at least transiently,
during virus–cell fusion. By interacting simultaneously with the membrane interfaces and other critical hydro-
phobic surfaces, we hypothesize that peptide entry inhibitors can act by changing the physical chemistry of
themembranes, and the fusion protein interfaces bridging them, and by doing so interferewith the fusion of cel-
lular and viral membranes. Based on this idea, we propose that an approach that focuses on the interfacial hydro-
phobicity of putative entry inhibitors could lead to the efﬁcient discovery of novel, broad-spectrum viral entry
inhibitors. This article is part of a Special Issue entitled: Interfacially Active Peptides and Proteins. Guest Editors:
William C. Wimley and Kalina Hristova.
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ticle, showing its classical enveloped virus architecture. The lipid bilayer membrane is
bounded on the inner surface by electron-dense matrix proteins (m). The membrane is
packed with 16 nm long spikes(s) made of the Class I fusion protein hemagglutinin,
here in the pre-fusion (neutral pH) state.1. Introduction
Enveloped viruses are an ancient and ubiquitous class of human
pathogen with infection rates and mortality rates that are often
expressed as measurable percentages of the entire human population
[1,2]. This class includes many well-known viruses such as inﬂuenza,
human immunodeﬁciency, hepatitis C, small pox, chicken pox, yellow
fever, herpes, measles and many more. It also includes tropical patho-
gens of signiﬁcant and growing global public health concern (e.g. den-
gue, lassa and chikungunya viruses), viruses that have recently elicited
fears of novel and deadly global pandemics (e.g. avian inﬂuenza, SARS
and MERS viruses) and viruses with signiﬁcant biothreat potential
(e.g. ebola, hantaviruses, Rift Valley fever virus, and most of the viruses
mentioned above). In this review, we discuss the discovery, develop-
ment, characterization andmechanism of action of peptides that inhibit
entry of enveloped viruses into host cells.
Over the past few decades peptides have steadily gained importance
in drug design and delivery. Increasingly, focus is shifting toward the
development and reﬁnement of techniques for identifying synthetic
peptides as drug candidates. Bioactive peptides have been discovered
by the use of naturally occurring peptides, through rational engineering,
through high-throughput screening, or by structure-based design using
sequences fromknown regions of proteins [3]. These factors are respon-
sible for the emergence of peptides as a growingmarket in the pharma-
ceutical industry. Currently there are about 100 peptide based drugs on
the market [4], constituting about 10% of the entire drug market [5].
As we describe below, one effective peptide entry inhibitor of an
enveloped virus is approved for use in humans [6] andmore are in clin-
ical trials [7,8].Many other peptide entry inhibitors of enveloped viruses
have been described in the scientiﬁc literature. In this reviewwe discuss
the surprising observation that the majority of known peptide entry
inhibitors, which have been discovered by an extraordinary diversity
of approaches, share a common physical chemistry: they are somewhat
hydrophobic and amphipathic with a propensity for binding to lipid
membranes. We hypothesize that their shared physical chemistry
could result in a sharedmechanismof action; one that enables a generic
approach to the discovery of broad-spectrum peptide entry inhibitors
for enveloped viruses.
2. Enveloped viruses
2.1. Entry of enveloped viruses into cells
The genomes of all enveloped viruses enter cells through a sequen-
tial, multistep process that requires i) virus binding to cell surface recep-
tors and ii) fusion of the viral membrane with a cellular membrane [9].
These essential steps occur by an incompletely understood process in
which viral fusion proteins (i.e. envelope glycoproteins, spike proteins,
see Fig. 1) mediate a temporally and spatially coordinated close contact
between the cellular and viral membranes while simultaneously
perturbing the continuity of the membranes with hydrophobic seg-
ments. For most enveloped virus families these events are triggered by
endocytosis of surface-bound virus and subsequent endosomal acidiﬁ-
cation. For a few viruses, such as HIV, fusion is triggered by conforma-
tional changes that occur upon binding to cell surface receptors and
co-receptors and is not entirely dependent on endosomal acidiﬁcation.
The fusion proteins of enveloped viruses can be grouped into several
distinct classes based on the protein secondary and tertiary structure.
Class I fusion proteins are predominantly α-helical trimers that foldinto an elongated 6-helix bundle [10–12]. This class includes the
well-known “spike” proteins of inﬂuenza (hemagglutinin) and
HIV (gp160). Class II fusion proteins are deﬁned by their elongated,
multi-domain, β-sheet rich structure and are found, for example, in
ﬂaviviruses. Class II fusion proteins are dimeric in the pre-fusion conﬁg-
uration, but transition to a trimeric state during low pH-induced fusion
[13]. Class III fusion proteins havemixedα/β structure and are found in,
for example, the herpes viruses [14].
Despite the structural diversity of their fusion proteins, the entry
mechanisms of enveloped viruses share critical biological activities
and structural signatures (Fig. 2). For all classes, cell surface binding is
driven by a speciﬁc chain or domain in a fusion protein or protein com-
plex that is distinct from the domain/chain that drives fusion of the viral
envelope with the cellular membrane. Membrane fusion is driven by
large conformational rearrangements of the fusion protein that expose
a hydrophobic fusion peptide or fusion loop while also simultaneously
presenting other hydrophobic sequences of the fusion protein to cata-
lyze membrane fusion [15–17].
In Fig. 2we show schematic structures of representative Class I, Class
II and Class III viral fusion proteins in the pre- and post-fusion states. In
addition to the hydrophobic fusion peptide (which is a terminal peptide
in Class I proteins, an internal loop in Class II proteins and a pair of fusion
loops in Class III fusion proteins) viral fusion proteins also have other
hydrophobic sequences that likely interact with membranes and con-
tribute to the fusion process. For example, many have a conserved, hy-
drophobic, aromatic-rich domain adjacent to the membrane-spanning
helix domain. InHIV, this so called “membrane proximal ectodomain re-
gion” or MPER is highly conserved and is critical for function [6]. The
MPER sequence of HIV gp41 is also the epitope for one of the fewbroad-
ly neutralizing antibodies against HIV [18]. MPER is very hydrophobic,
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involves membrane binding and destabilization [20]. Class I viral fusion
proteins also have other internal hydrophobic segments, including leu-
cine zipper like-motifs that lie at the interfaces between helical heptad
repeat domains thatmay also become exposed, at least transiently, dur-
ing the conformational rearrangements that drive fusion [21]. Class II fu-
sion proteins have similar features. For example, they often have
conserved aromatic/hydrophobic juxtamembrane domains, called
“stem” domains, that (like MPER) interact strongly with membrane in-
terfaces and can form amphipathic helixes [22]. In addition to the stem
domain, Class II fusion proteins have other hydrophobic regions that are
likely involved in the fusion process [16,17]. Interestingly, arenavirus
Class II fusion protein complexes include a so called stable signal pep-
tide (SSP) domain, a conserved and required protein which contains
two transmembrane helical segments connected by a loop domain
[23–25]. Unlike most signal sequences, arenavirus SSPs remain stably
inserted in the viral envelope and associate with the fusion protein in
a complex. These hydrophobic SSPs, whose function remains unknown,
have the potential to provide additional hydrophobic surface to the pro-
tein–membrane interfaces that arise during fusion. Similarly, the archi-
tecture of Class III fusion proteins contains hydrophobic patches that
may participate in fusion [14] although less is known about Class III fu-
sion proteins, overall.
2.2. Viral entry inhibition: an underutilized therapeutic target
It is reasonable to hypothesize that the function of all viral fusion
proteins is similarly dependent on the exposure of multiple hydropho-
bic segments to form a continuous hydrophobic surface bridging the
viral and cellular membranes and allowing for fusion to take place by
mixing the lipids in the two membranes. This hypothesis suggests that
a broad-spectrum approach to entry inhibition of enveloped viruses
may be possible by targeting, through physical chemistry, the hydropho-
bic surfaces on themembranes and fusion protein that are exposed dur-
ing fusion. Highlighting the potential vulnerability of the fusion process,
it can be inhibited by changes in protein structure [26], by changes in
membrane physical properties [27], by changes in the timing of protein
conformational changes [28] or by the addition of antibodies, peptides
or small molecules that bind the fusion protein [24,29–31].
For these reasons, viral entry would seem to be a vulnerable target
for antiviral countermeasures. Indeed, there are smallmolecules that in-
hibit viral fusion and entry, including inhibitors of inﬂuenza [29] and the
arenavirus, junin [24]. These compounds function by binding to the fu-
sion protein and inhibiting virus–cell fusion [24,29]. However, small
molecules are not the only possible approach to entry inhibition and
may not be ideally suited for interacting with a large conformationally
ﬂuid interface between the hydrophobic surfaces that we hypothesize
to be critical for inhibition of entry. Larger molecules, such as peptides
or other polymers that interact with the hydrophobic membrane–
protein interfaces, may also bewell suited to be entry inhibitors. For ex-
ample, it was shown that viral fusion peptides, which are hydrophobic
and bind to membranes [32], can inhibit viral entry [33,34]. Perhaps
most importantly, if inhibition occurs due to physical chemical interac-
tions with a transient, hydrophobic protein–membrane interface, then
broad-spectrum entry inhibition, without rapid selection for resistance,
is possible. In this review we discuss the many known peptide entryFig. 2. Pre- and post-fusion structures of representative viral fusion proteins of Classes I–III. The d
viruses are shown in the pre-fusion (virion) and post-fusion states. Panel A. Thedomain architec
(TM), a Class I VFP is indicated: red: fusion peptide, orange: amino terminal helix (aka helical r
minal helix (aka HR2 or CHR), blue: membrane proximal region (MPER aka aromatic domain)
structure: 3F4Y, [136]. Fusion peptide in post-fusion state: 1ERF, [137]. MPER structure: 1JAU, [
coprotein (E), a Class II VFP is indicated: green (domain I), yellow (domain II) and blue (domai
membrane protein (M) is depicted in orange. Pre-fusion structure:1OAN, [139]. Post-fusion str
Rhabdoviridae) glycoprotein (G), a Class III VFP is indicated: green (domain I), yellow (domain II
respectively. Pre-fusion structure: 2J6JX, [141]. Post-fusion structure: 2CMZ, [142]. The left port
Zhang et al. [143].inhibitors of enveloped viruses and show that they are, almost always,
hydrophobic and/or amphipathic sequences with a propensity for
membrane interface binding.
2.3. Enfuvirtide: a peptide entry inhibitor drug against HIV
HIV is a retrovirus that targets and depletes CD4+ T-cells [35–37]
and is responsible for causing AIDS. Globally, tens of millions of people
are infected with HIV, leading to 1–2 million deaths per year. The char-
acteristic structural feature of HIV is the presence of protein spikes on its
envelope surface [38,39]. Originally existing as a single chain, gp160, the
fusion protein of newly made viruses undergoes proteolytic processing
in the Golgi complex by intracellular proteases, producing two subunits,
gp120, the distal domain and, gp41, the membrane spanning domain,
which is a Class I fusion protein [10]. The collective and co-operative ac-
tions of gp120 and gp41 are responsible for promoting viral genome
entry into the host cell. The heavily glycosylated gp120 protein is re-
sponsible for the recognition and binding of the virus to the host cell,
as it binds to the CD4 membrane protein and the co-receptors CCR5
and CXCR4. Binding triggers the conformational changes in gp41 that
ultimately lead to fusion of the viral membrane with the host cell mem-
brane [40,41]. Like other Class I fusion proteins, gp41 ismade of a hydro-
phobic fusion peptide on the N-terminus and an α-helical N-terminal
helical heptad repeat (NHR) sequence which is connected to a C-
terminal helical heptad repeat (CHR) by a loop domain [10]. Following
the CHR is the aromatic/hydrophobicMPER domain, a membrane span-
ning helical anchor and a C-terminal domainwhich also containsmem-
brane interacting sequences [20,42]. During entry, the N-terminal
fusion peptide of gp41 becomes exposed and likely interacts with the
host cell membrane. At the same time, the N- and C-terminal heptad
repeat sequences undergo a major transition from the native state to a
more extended helical conformation. The heptad repeat domains drive
the assembly of an elongated 6-helix bundle in the trimer. These confor-
mational transitions allow the fusion peptide and other hydrophobic se-
quences, such as MPER, to destabilize the viral and cell membrane, and
also bring the membranes into close proximity, ultimately resulting in
mixing of the viral and cell membranes, creating a passage for the re-
lease of the viral genome in to the cell [37,43].
In 1990 Qureshi et al. [44] showed that a peptide named CS3, de-
rived from the loop/C-helix heptad repeat (CHR) domain (referred to
as the “fusion initiation region” [45] of the then hypothetical struc-
ture of gp41), could block the entry of HIV into cells [38]. The discov-
ery of CS3 catalyzed the search for other gp41-derived peptide entry
inhibitors for HIV, which ultimately led to the discovery, develop-
ment and licensure of enfuvirtide (also known as FUSEON or T20).
Enfuvirtide is a peptide entry inhibitor for HIV that was approved
by the US Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) for human use in 2003. This injectable an-
tiviral peptide drug is an effective HIV therapeutic belonging to a
unique class of entry inhibitor, adding to the already existing classes
that include reverse transcriptase inhibitors and HIV protease inhib-
itors [46,47].
Enfuvirtide is a 36-residue peptide that is derived from an amphi-
pathic segment of the CHR region of gp41 including the C-terminal
end of the CHR and a portion of the aromatic/amphipathic membrane
proximal ectodomain region (MPER). The C-terminal half of enfuvirtideomain architectures of the three known classes of viral fusion proteins (VFP) of enveloped
ture of human immunodeﬁciencyvirus (family:Retroviridae) transmembrane glycoprotein
egion 1, HR1 or NHR), yellow: T loop containing the dicysteine bridge, green: carboxyl ter-
, and indigo: transmembrane domain (tm). Pre-fusion structure: 4NCO, [135]. Post-fusion
138]. Panel B. The domain architecture of dengue virus (family: Flaviviridae) envelope gly-
n III). The fusion loop, stem and tm helices of E are red, indigo and violet, respectively. The
ucture: 4GSX, [140]. Panel C. The domain architecture of vesicular stomatitis virus (family:
) and blue (domain III). The fusion loops, stem and tmhelices of G are red, indigo and violet,
ion of Panel B and the depiction of cellular and viral membranes aremodiﬁed from Fig. 4 of
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sequence has a strong propensity to form an amphipathic α-helix,
which is the structure it forms in the post-fusion 6-helix bundle of
gp41. Inhibition of viral infection by enfuvirtide in vitro is through inhi-
bition of entry [6,46–51], although the exact molecular mechanism
is not entirely clear. Enfuvirtide may bind to multiple regions of
gp120/gp41 [6,46–51]. Enfuvirtide was shown in one study to inhibit
genome entry fusion at a step after some lipid mixing had taken place,
but before opening of the fusion pore [52]. Enfuvirtide does not form a
stable 6-helix bundle in the presence of NHR sequences, unlike some
other CHR-derived peptides [48]. Direct evidence of strong, sequence-
speciﬁc binding of enfuvirtide to gp41 has not been observed, thus it
has been suggested that it interacts with transient fusion intermediate
states of gp41. A slightly different variant, DP178, binds strongly to syn-
thetic membranes and was suggested to inhibit fusion pore formation
[52] via the effect of direct membrane interactions on gp41 structure
and dynamics.
In any case, the success of enfuvirtide in the clinic against a difﬁcult-
to-treat, chronic virus demonstrates the potential utility of peptide
entry inhibitors as viral therapeutics. In this review we discuss the
many peptide entry inhibitors of enveloped viruses that have been iden-
tiﬁed and characterized since the discovery of enfuvirtide and connect
them by hypothesizing an overlapping mechanism of action.
3. Identiﬁcation of membrane-interacting sequences using the
Wimley–White interfacial hydrophobicity scale
Prompted by the discovery and characterization of CS3, enfuvirtide
and other hydrophobic/amphipathic peptide entry inhibitors, one of
us (R.F.G.) has taken, in recent years, a novel, rational approach to suc-
cessfully identify numerous peptide entry inhibitors against enveloped
viruseswith Class I, Class II and Class III fusion proteins. In this approach,
potential peptide entry inhibitors are identiﬁed by scanning viral fusion
proteins for sequences that have a propensity for membrane binding
using the Wimley–White interfacial hydrophobicity scale [53,54] (see
next section), followedbydirect experimentalmeasurement of antiviral
activities of the small number of candidate sequences to identify those
with optimal antiviral activity. Later, we discuss each of these peptide
entry inhibitor studies and show that this approach is effective, efﬁcient
and broadly generalizable.
3.1. The Wimley–White interfacial hydrophobicity scale (WWIHS)
Theunique physical–chemical environment at thewater–membrane
interface drives a unique class of hydrophobic interaction that is domi-
nated by the contribution of aromatic residues [53–55]. To identify and
quantitate interfacial, membrane-binding sequences of peptides and
proteins it is appropriate to use the Wimley–White interfacial hydro-
phobicity scale (WWIHS), an experimentally-determined free energy
scale that represents the propensity for individual amino acids, in
the context of peptide sequences, to partition from water into a phos-
phatidylcholine interface [53,56]. Importantly, the WWIHS is based on
whole-residue free energies, and thus has a true zero point that distin-
guishes peptide sequences that have a propensity to interact with
membranes from those that do not. There are two ways that WWIHS
scores have been used in the literature and in this review. i) WWIHS
is used in the “hydropathy analysis”mode to calculate a slidingwindow
hydrophobicity score along the sequence of a protein. This approach
identiﬁes segments of a protein with a propensity to interact with
membrane interfaces. ii) WWIHS is used in the “totalizer” mode to
calculate the overall interfacial hydrophobicity of a particular peptide
sequence. This approach is an accurate predictor of membrane interac-
tion propensity [57]. Here, we calculate WWIHS values by default at
low pH (where aspartate and glutamate are uncharged and histidine
is charged) to simulate the low pH environment of the endosome
(pH 5.0–5.5) where most viral fusion takes place. In support of thisassumption, we note that the pKa values of acidic groups on peptides
[58,59] and other molecules [60] are shifted into the range of 6.0 to
7.5 by environmental factors when they are bound to membranes.
WWIHS values are calculated assuming random coil peptides
partitioned into the bilayer interface. The values are thusminimumpos-
sible values, as ΔG can only get more favorable if peptide binding pro-
motes an increase in secondary structure, as is often the case. The
possible increase in ΔG with secondary structure (favoring membrane
binding) has been estimated to be between 0.3 and 0.6 kcal/mol/resi-
due [58,59] and thus can be a very large effect.
The interfacial helical hydrophobic moment (iHHM) is another
important physical–chemical factor that is relevant to membrane inter-
actions and secondary structure formation by peptides bound to mem-
brane interfaces. The iHHM quantiﬁes the degree to which a peptide
sequence would have segregated hydrophobic and hydrophilic faces if
it folded into an α-helix [61]. A peptide with a large iHHM can interact
strongly with membranes as a helix due to partitioning–folding cou-
pling [58,59] even when its WWIHS score is not positive overall.
Although the exact relationship between partitioning and folding can-
not be extractedquantitatively from iHHM, it provides useful landmarks
as shown in Table 1. In this review, we show WWIHS scores for all
peptides and include the iHHM of peptide entry inhibitors when the
value is large enough to potentially be a factor in membrane interaction
(iHHM ≥ 2.0).
Wimley–White interfacial hydrophobicity scale scores and helical
hydrophobic moments (at neutral or low pH) can be calculated using
the “Membrane Protein Explorer” (MPEX) web utility (http://blanco.
biomol.uci.edu/mpex/). See supplemental information for a tutorial on
using the MPEX utility to calculate WWIHS and iHHM.
3.2. Dengue virus and West Nile virus
The initial proof-of-concept that WWIHS-selected peptides can
function as entry inhibitorswas byHrobowski et al. [31]. They identiﬁed
peptides that successfully inhibited the ﬂaviviruses dengue and West
Nile, classiﬁed by the US National Institute of Allergy and Infectious
Disease (NIAID) as a category A and category B priority pathogens, re-
spectively. The global health crisis caused by dengue virus [62–64] dem-
onstrates the critical importance of novel therapeutics to public health.
Dengue is a vector-borne viral disease, transmitted to humans via in-
fected Aedes aegypti mosquitoes in tropical and sub-tropical regions,
with recent expansion to temperate climates. The global incidence of
dengue has increased by 30-fold in the past ﬁve decades. Despite formi-
dable efforts, no licensed vaccine or approved therapeutic options are
available. Dengue infections vary in severity from asymptomatic, to fe-
brile manifestations, to potentially life-threatening dengue hemorrhag-
ic fever (DHF) or dengue shock syndrome (DSS). The estimated annual
number of infections worldwide stands at 100 million, but this number
may be underreported. The annual number of DHS or DSS cases is be-
tween 500,000–1 million, with an estimated 22,000 deaths, mainly
among children.
West Nile virus is also a ﬂavivirus. The emergence and spread of
West Nile virus in North America is a particularly well-documented ex-
ample of the potential for sudden emergence of public health risk posed
by vector borne enveloped viruses. West Nile virus is endemic in Asia,
the Middle East and Australia. However, in 1999 West Nile virus infec-
tions in humans were identiﬁed, and several deaths were reported in
Queens, New York, probably after the viruswas introduced by an infect-
ed bird or animal [65]. The virus spread very rapidly across North
America, and then to Central America, rising to about 10,000 identiﬁed
cases, and about 300 deaths in the US by 2003 [65]. Because the disease
is usually mild, the actual number of cases may be as much as 100-fold
larger than the reported number [65]. West Nile virus is now endemic
across North America. Morbidity and mortality from West Nile virus
do occur, usually resulting from viral encephalitis or meningitis [65].
This example illustrates the urgent need for broad-spectrum therapies
Table 1
Signiﬁcance of Wimley–White interfacial hydrophobicity scale (WWIHS) score and of interfacial helical hydrophobic moment (iHHM) score. Values have units of kcal/mol and are
calculated using the MPEx web utility (http://blanco.biomol.uci.edu/mpex/). See supplemental information for a tutorial on using MPEx to calculate WWIHS and iHHM scores.
Signiﬁcance of Wimley–White interfacial hydrophobicity scale (WWIHS) score
Score Signiﬁcance
N8 Very strong membrane partitioning. Free peptide is not readily observable. Binding is likely to drive secondary structure.
6–8 Strong membrane partitioning. Peptide is mostly bound.
4–6 Moderate membrane partitioning. Free and bound peptide are both observable. Positive interfacial helical hydrophobic moment (iHHM) will increase binding and helicity.
2–4 Weak membrane partitioning of random coil peptides. Free peptide is more abundant than bound peptide. Positive iHHM will increase binding and increase helicity of
bound peptide.
0–2 Very weak membrane binding of random coil peptides. Bound peptide is difﬁcult to detect. High helical hydrophobic moment (iHHM) can still drive strong binding.
b0 No propensity to partition into membranes as a random coil. High iHHM can still drive strong membrane binding as an α-helix.
Signiﬁcance of interfacial helical hydrophobic moment (iHHM)
Score Signiﬁcance
N10 Nearly ideal amphipathicity. Likely to bind strongly to membranes as an α-helix independent of WWIHS score.
6–10 Very strong amphipathicity. Strong membrane binding and high α-helical secondary structure content are likely.
4–6 Strong amphipathicity. Strong enhancement of binding is likely. Formation of some α-helical structure is likely.
2–4 Moderate amphipathicity. Enhancement of membrane binding and helicity is likely for sequences with positive WWIHS score.
0–2 Weak amphipathicity. Little effect on binding or structure, which will be determined by WWIHS score.
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demic might be caused by an enveloped virus that causes high morbid-
ity and mortality.
Both of these ﬂaviviruses enter cells via receptor mediated endocy-
tosis [66]. Once internalized, endosomal acidiﬁcation occurs and
the viral fusion protein E, a Class II fusion protein, undergoes a major
structural rearrangement which is necessary for the initiation of fusion
of the viral and cell membranes. To ﬁnd putative entry inhibitors,
Hrobowski et al. [31] analyzed the fusion proteins of dengue and West
Nile virus using WWIHS. A few potential inhibitor candidates were
selected based on positive WWIHS scores. Figs. 3 and 4 show the active
peptides selected fromdengue andWestNile virus surface glycoproteins,Fig. 3. Discovery of dengue virus peptide entry inhibitors using WWIHS. The Class II fusion pro
sequences shown in color. A partial monomeric structure of E [PDB ID: 1OK8] is shown with th
virus in vitro [31] as shown.respectively. Peptideswith positiveWWIHSwere tested for their ability
to inhibit viral plaque formation in vitro. The peptides DN59 from den-
gue virus (WWIHS=7.0, iHHM=5.4) andWN83 fromWest Nile virus
(WWIHS= 7.6, iHHM= 2.3), which are very hydrophobic and amphi-
pathic, proved to be themost effective against dengue andWest Nile vi-
ruses, respectively with IC50 values around 10 μM [31].
DN59 is an aromatic/hydrophobic stem domain peptide that was
further studied by Lok et al. [67]whoobserved a dose-dependent expul-
sion of the viral genome upon incubation of virus with peptide, indicat-
ing a direct virolytic effect. DN59 formed lesions in viral membranes
that were observable by cryo transmission electron microscopy. In
agreement with the direct virolytic effect, Lok et al. also showed thattein, E, of dengue was analyzed using WWIHS to identify putative membrane interacting
e WWIHS positive sequences in color. These peptides were tested for inhibition of dengue
Fig. 4.Discovery ofWest Nile virus peptide entry inhibitors usingWWIHS. The Class II fusion protein, E, was analyzed usingWWIHS to identify putativemembrane interacting sequences
shown in color. A partial monomeric structure of E [PDB ID: 2I69] is shown with the WWIHS positive sequences in color. These peptides were tested for inhibition of West Nile virus
in vitro [31].
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has potentmembrane permeabilizing activity in synthetic lipid vesicles.
On the other hand, unlike most vesicle-permeabilizing peptides, DN59
has no toxic effect on mammalian cells. Although the active peptides
were initially expected to interact speciﬁcally with the fusion proteins,
the observed non-speciﬁc membrane interactions are consistent with
the physical chemistry-based identiﬁcation of potential candidates by
WWIHS [53,67]. Schmidt et al. [68,69] studied a series of closely related
dengue virus stem domain peptides and showed that the peptides bind
strongly to viruses prior to attachment and are carried into endosomes
alongwith the virus. Interestingly DN59 andWN83 showed incomplete
cross reactivity: DN59 is active against dengue and West Nile viruses,
butWN83 is active only against West Nile virus, but not against dengue
virus. We discuss below numerous similar cases of incomplete cross-
species inhibition by peptide entry inhibitors.
3.3. Severe acute respiratory syndrome corona virus (SARS-CoV) and
murine hepatitis virus
SARS-CoV is a coronavirus that predominantly targets the respirato-
ry tract of humans with symptoms ranging from fever, headache, and
cough, to fatal respiratory distress. After its initial outbreak in China,
SARS CoV infected at least 8000 individuals in 2003 leading to ~700 fa-
talities [33,70]. The high mortality rate of SARS elicited fears of a deadly
global pandemic [33,71]. Very recently, a related coronavirus with
similarly high mortality, called the Middle East respiratory syndrome
coronavirus, or MERS-CoV, has emerged [20,72]. The rapid rise and
spread of MERS once again raised fears of a global pandemic caused
by a virus for which there are no known therapeutics. Coronaviruses
are enveloped viruses that follow the classical pathway of entry and in-
fection as other enveloped viruses. The surface glycoprotein or fusion
protein of the virus, called the S protein, is a typical Class I fusion protein
and is divided into two subunits. The S1 subunit is responsible for the
binding of the virus to the host cell receptor and the S2 subunit drives
fusion of the viral and host membrane [71,73]. To identify inhibitory
peptides against SARS CoV, Sainz et al. [71] analyzed the S2 subunit ofthe SARS CoV fusion protein usingWWIHS. They identiﬁed ﬁve peptide
sequences with high WWIHS scores: SARSWW-I–SARSWW-V (Fig. 5).
The hydrophobic SARSWW-I (WWIHS=6.2) sequence is the fusion pep-
tide [22], peptides II, III and IV are found just outside of the heptad-
repeat sequences between the N- and C-helical heptad repeat domains.
SARSWW-V corresponds to the aromatic-rich juxtamembrane domain,
analogous to the stem domain from which DN59 was obtained.
Sainz et al. showed that the peptides from all ﬁve regions causedmeasur-
able inhibition of virus infection, and that SARSWW-III (WWIHS = 5.7)
and SARSWW-IV (WWIHS = 7.1) showed the greatest inhibition in vitro
with IC50 of 2–4 μM. SARSWW-III and SARSWW-IV were hypothesized to
inhibit the conformation change required by the S2 protein during
fusion, although the exact mechanism of action remains unknown.
In the same paper, Sainz et al. showed that a peptide from the Class I
murine hepatitis virus, corresponding to the same hydrophobic segment
as SARSWW-IV inhibited MHV and SARS in vitro with IC50 = 4 μM.
However, the equivalent SARS peptide did not inhibit MHV.
By successfully using the Wimley–White interfacial hydrophobicity
scale to identify peptide entry inhibitors against a second pair of viruses
with a different class of fusion protein (Class I vs. Class II), Garry and col-
leagues demonstrated the power and generality of their approach [33,71].
3.4. Human cytomegalovirus (HCMV)
HCMV is a double stranded DNA virus and is amember of the herpes
virus family. HCMV, which infects humans through an oral route, is
widespread and often asymptomatic. However, infection just before or
during pregnancy is associated with high morbidity and mortality for
the fetus [74]. Similarly, its widespread abundance leads to high rates
of infection and disease in immunocompromised patients, where it
can lead to retinitis and blindness. HCMV has a Class III fusion protein
in a complex composed of glycoproteins gB, gH and gL. Glycoprotein B
(gB) has the primary role in binding and fusion of the virus with the
host cell [75,76]. HCMV can enter many different cell types using an
array of envelope glycoproteins, in conjunction with gB. While fusion
and entry often occur after endocytosis and acidiﬁcation, there is also
Fig. 5. Discovery of SARS coronavirus peptide entry inhibitors usingWWIHS. The Class I fusion protein, S2, of SARSwas analyzed usingWWIHS to identify putativemembrane interacting
sequences shown in color. A structure for the core trimer of the SARS S2 protein in the prefusion state is shown [PBD ID: 2BEQ]. Only one of theWWIHS positive peptides is included in the
structure. These peptides were tested for inhibition of SARS virus in vitro [71].
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nine peptides selected from gB based on their propensity for mem-
brane partitioning as per the WWIHS (Fig. 6). Four of these peptides
(WWIHS = 3-5) showed ≥50% inhibition of HCMV at 1–5 μM peptide
[77]. The same peptides also inhibited herpes simplex virus, measles
virus and a vesicular stomatitis pseudotype virus.
These authors also tested the effect of the same peptide entry inhib-
itors conjugated to the polycationic tat cell penetrating peptide [78].
They observed that tat conjugation increased antiviral activity signiﬁ-
cantly against all viruses tested. Importantly, both pre-incubation of
cells with tat-conjugated peptides and post-infection treatment provid-
ed signiﬁcant protection. Peptides that were not conjugated to tat had
nomeasurable inhibitionwhen added 24 h post infectionwhile tat con-
jugated peptides had IC50 values between 1 and 10 μM at 24 h. As tat-
cargo conjugates are known to bind to cells and enter by endocytosis
[79], this result suggests strongly that entry inhibition takes place in
the endosomal compartments which can be readily accessed by tat-
conjugated peptides. It is possible that many peptide entry inhibitors,
by virtue of their propensity for membrane binding, enter endosomal
pathways along with viruses.
The active peptides discovered by Melnik et al. have some overlap
with peptides identiﬁed in a different study of the related herpes sim-
plex virus. In that study, Akkarawongsa et al. [80] used an entirely dif-
ferent approach to identify entry inhibitor peptides from the Class III
fusion protein of HSV (discussed in detail below). Those authors identi-
ﬁed a small number of inhibitory peptides, some of which are highly
analogous to the ones identiﬁed by Melnik et al., and which likewise
have positive WWIHS scores.
3.5. Rift Valley fever virus (RVFV)
Rift Valley fever virus is an enveloped RNA virus that belongs to the
Bunyaviridae family. RVFV infection, which is sometimes accompaniedby severe hemorrhagic disease, can be fatal to both humans and live-
stock [81–83]. This mosquito-borne virus is endemic in parts of Africa
and the Arabian peninsula and has emerged as a signiﬁcant public
health concern [81–83] and as a potential biothreat agent. As a conse-
quence, RVFV is an NIAID category A priority pathogen, the highest pos-
sible priority. The Gn and Gc surface glycoproteins are responsible for
the binding and entry of the virus to the host cell. Gn is a Class II fusion
protein. The mechanism of fusion for RVFV has not been well studied,
however it can be modeled using the well characterized fusion process
of other Class II fusion proteins [82,84]. To identify inhibitory peptides
for RVFV, Koehler et al. [82] identiﬁed candidates from the sequence
of the Gn fusion protein that have positive WWIHS scores (Fig. 7).
They identiﬁed 5 regions of positive WWIHS score, which included the
fusion loop peptide and the hydrophobic, aromatic juxtamembrane
“stem” domain. Because the stem domain peptides had the best activity,
the authors tested a series of truncation and translation variants. The
most active peptide, RVFV-6, (WWIHS = 11.5) is very hydrophobic
and showed ≥95% inhibition of RVFV at 25 μM concentration [82]
with an IC50 around 5–10 μM. The authors showed that RVFV-6 binds
directly to both cells and virus, and probably inhibits viral entry by
inhibiting the fusion step. In support of the somewhat generalizable
nature of membrane binding peptide entry inhibitors, RVFP-6 also
inhibits an enveloped virus with a Class I fusion proteins (Ebola) and
an enveloped virus with Class III fusion proteins (vesicular stomatitis
virus). However, it did not inhibit any of three equine encephalitis virus-
es tested.
Interestingly, one of theWWIHS-positive peptides from the RVFVGn
protein actually increased virus infection at 25 μM, while inhibiting it at
50 μM.Apeptide-dependent increase in infection is an effectwe also ob-
served in a screen of various membrane binding peptides (unrelated to
viral fusion proteins) against a lassa pseudotype virus (AR Hoffmann,
WC Wimley and RF Garry, unpublished). Of 14 interfacial binding pep-
tides tested in vitro, 9 inhibited lassa pseudotype virus at ≤50 μM,
Fig. 6. Discovery of human cytomegalovirus peptide entry inhibitors using WWIHS. The Class III fusion protein, Gb, of CMV was analyzed using WWIHS to identify putative membrane
interacting sequences shown in color. No homologous three dimensional structure is available for this protein. These peptides were tested for inhibition of CMV virus in vitro [77].
Fig. 7. Discovery of Rift Valley fever virus peptide entry inhibitors using WWIHS. The Class II fusion protein, Gn, of RVFV was analyzed using WWIHS to identify putative membrane
interacting sequences shown in color. Variants and truncations were tested to identify the most potent inhibitor. These peptides were tested for inhibition of RVFV and other viruses
in vitro. A partial monomer structure of Gn [PDB ID: 4HJC] is shownwith theWWIHS positive stemdomain shown in color. The stemdomain in bluewas absent from the crystal structure
of Gn. Here it is modeled as an α-helix [82].
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than two-fold, while inhibiting it at 50 μM. Given the hypothesis we
are discussing here, it is perhaps not surprising that hydrophobic
membrane-interacting peptides have the capacity to promote fusion
and viral entry. However, the vast majority of peptides discussed in
the literature are inhibitory.
3.6. Inﬂuenza virus
Inﬂuenza virus is a highly pathogenic enveloped virus with a single
stranded RNA genome. It belongs to the Orthomyxoviridae family [85]
and is responsible for annual seasonal illnesses as well as occasional
global pandemics that occur when new strains arise by recombination.
In terms of morbidity and mortality, one of the worst modern pan-
demics was the “Spanish Flu” outbreak in 1918, caused by an H1N1
strain of inﬂuenza A virus which killed as much as 1–3% of the world's
population globally [86]. The recently identiﬁed H5N1 “avian” inﬂuenza
virus has a very high mortality rate in humans but is not highly in-
fectious [87]. On the other hand, the so-called “swine ﬂu” or H1N1 pan-
demic of 2009 infected 10–20% of the global human population
(including 30-–40% of school-aged children) in a single season [88].
The US Center for Disease Control (CDC) estimates that up to 575,000
people died [89] during this pandemic, which actually reﬂects a rela-
tively low mortality rate, given the high infection rate. Every annual
ﬂu season raises the possibility of a highly infectious inﬂuenza pandem-
ic that also has high mortality, highlighting the urgent need for broad
spectrum antiviral therapies.
Inﬂuenza virus has two surface glycoproteins, hemagglutinin (HA)
and neuraminidase (NA), which play important roles in the entry of
the virus into the host cell and the release of new virus particles from
the host cell, respectively. HA was the ﬁrst viral fusion protein to be
characterized and is the archetypal trimeric Class I fusion protein.
The precursor HA0 is activated by proteolytic cleavage to give two sub-
units HA1 and HA2. The globular HA1 is responsible for binding of the
virus to sialic acidmoieties on protein and lipids on the host cell surface.
The membrane-anchored HA2 chain is responsible for promoting
membrane fusion. Upon binding, the virus is internalized by clathrin
mediated endocytosis. In the late endosomal stage, acidiﬁcation occurs,Fig. 8.Discoveryof inﬂuenza virus peptide entry inhibitors usingWWIHS.Hemagglutinin, the Cl
interacting sequences shown in color. A partial structure of an HA1 and HA2 trimer in the prefu
example shown is for anH3 variant of hemagglutinin. Variants and truncationswere tested to id
in vitro.triggering a large-scale conformational change in the native HA2 struc-
ture that exposes its N-terminal fusion peptide and other hydrophobic
sequences and brings the membranes into close proximity for fusion
[23,90,91].
Garry, Wilson and colleagues analyzed the HA2 fusion protein of
different strains of inﬂuenza A and discovered candidate entry in-
hibitors that showed robust inhibition in viral plaque assays [92]. The
best inhibitory sequences were from the “fusion initiation region”
(FIR) of HA2, comprising a hydrophobic segment of theN-helical heptad
repeat (NHR) domain of HA2. Several FIR-derived peptides from dif-
ferent strains of inﬂuenza were characterized, and the most active 16-
residue peptide, named FF-3, was identiﬁed. In Fig. 8 we show the
peptide sequence from several strains of virus. FF-3, from the H3 strain
of inﬂuenza, (WWIHS = 5.2) showed the maximum inhibition in viral
plaque assays, inhibiting multiple strains of inﬂuenza A and B in vivo
with IC50 values≤ 1 μM. FF-3 is currently in phase 1 human clinical trials
[7,8]. Mechanism of action studies suggests that FF-3 is an entry inhibi-
tor despite the fact that it does not interact measurably with inﬂuenza
hemagglutinin at neutral or low pH (H Badani, RW Wilson, RF Garry
and WCWimley, unpublished).
3.7. Pichinde virus
Pichinde virus is a model arenavirus, a family that includes mul-
tiple NIAID Category A priority pathogens, including lassa, junin and
others. The only therapeutic used for arenaviruses is the nucleoside an-
alog ribavirin, which is an off-label use and is not optimal. Thus, as with
most classes of enveloped viruses, new classes of inhibitors against
arenaviruses are desperately needed. Arenaviruses have envelope gly-
coprotein complexes comprised of three protein chains: the receptor
binding domain, GP1; the Class I fusion protein, GP2; and an unusual
“stable signal peptide” (SSP) domain comprised of two transmembrane
helices [25] connected by a loop.
Spence et al. [93] examined the sequences of GP1 and GP2 of
pichinde virus using WWIHS and identiﬁed 12 peptides from regions
with positive WWIHS scores (Fig. 9). Five of the peptides had inhib-
itory activity against pichinde in vitro at concentrations b 100 μM. The
most active peptide, corresponds to the fusion peptide of GP2. Thisass I fusion protein of inﬂuenza,was analyzedusingWWIHS to identify putativemembrane
sion state [PDB ID: 1RD8] is shownwith the activeWWIHS positive sequence in color. The
entify themost potent inhibitor, FF-3. Thesepeptideswere tested for inhibition of inﬂuenza
Fig. 9. Discovery of pichinde virus peptide entry inhibitors using WWIHS. The GP1 and GP2 proteins of the fusion protein complex of pichinde were analyzed using WWIHS to identify
putativemembrane interacting sequence. No pichinde GP structure is currently available. These sequenceswere tested to identify themost potent inhibitor against pichinde in vitro [93].
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hydrophobic and inhibits pichinde with IC50 = 0.75 μM [93]. A second
highly active peptide AVP-p, LNLFKKTINGLISDSLVIR, (WWIHS = 2.4,
iHHM = 3.7) is a somewhat hydrophobic sequence from the N-helix
heptad repeat (NHR) domain of GP2 with a strong propensity to form
an amphipathic helix (Fig. 8). AVP-p inhibits pichinde with IC50 =
7 μM, and similarly inhibits pseudotype viruses with the envelope gly-
coproteins of the arenaviruses lassa, junin and machupo. At 7 μM, it
did not inhibit vesicular stomatitis, herpes simplex or measles viruses,
which belong to other families.
Both of these inhibitory peptides interact directly with synthetic and
viral membranes. Interestingly, AVP-p signiﬁcantly changes the ﬂuidity
and organization of the lipids, but it does not bind stably or measurably
to the GP2 fusion protein. Despite not interacting with GP2 directly,
AVP-p, by cryoTEM and biochemical assays, prematurely triggers the
fusion-competent state of GP2, even at neutral pH. Rather than promote
infectivity, premature fusion competence is inhibitory, consistent with
the proposed critical role of the timing of events for productive fusion.
An important conclusion from this work is that a peptide that interacts
directly with viral membranes can change their physical properties in a
way that affects the structure and function of the fusion protein. A similar
conclusion was drawn about the mechanism of action of DP178 against
HIV [52]. Because the same experiments have not been done with most
other peptide entry inhibitors described here, it remains possible that
the mechanism of AVP-p is shared by other peptide entry inhibitors.
3.8. Hepatitis C virus
Hepatitis C virus is an enveloped RNA virus of the ﬂavivirus family
that is transmitted by blood-to-blood contact such as by shared needles
in iv drug use or improperly sterilized medical equipment. Hepatitis C
virus persists chronically in many infected people, frequently leading
to hepatitis and liver cancer, both debilitating and costly diseases with
high mortality. In fact, deaths from HCV in the U.S. have recently
surpassed those caused by HIV [94]. At least several hundred million
people are infected with HCV worldwide [94,95].
HCV has two envelope glycoproteins, E1 and E2, each with its own
transmembrane helical anchor. They form a non-covalent dimer in theviral envelope. Their individual roles in cell surface binding and fusion
are still not entirely clear. While it had been proposed that E2 is the
fusion protein and that it has structural homology to Class II fusion pro-
teins, a recent crystal structure [96] showed that the E2 structure is not
homologous to any known class of viral fusion protein. Instead, bioinfor-
matics analyses of the HCV E1 protein suggest that it is a truncated Class
II fusion protein (Sabahi A., Dash S, Garry CE, Prabhu, R., Haislip, A.M.,
Uprichard SL,WimleyWC,McKeating, JA and Garry, RF, in preparation).
To identify HCV-inhibiting peptides, Sabahi [34] tested overlapping
18-residue peptides from E1 and E2, and also from the viroporin-like
p7 protein, for liposome disruption, liposome fusion and viral inhibition.
Peptides from ﬁve different segments of E1, E2 and p7 showed signiﬁ-
cant activity against liposomes. All ﬁve of these regions correspond to
regions of positive WWIHS scores (Fig. 10) and include the putative fu-
sion peptide of E1, and the aromatic juxtamembrane stem-like domains
of both E1 and E2. A sequence that had been proposed to be the fusion
peptide of E2 [97] was not active against liposomes and does not have
a positive WWIHS score and therefore is very unlikely to be a fusion
peptide [32].
When the same overlapping peptides were tested in an HCV
pseudovirus inhibition assay, four peptides were identiﬁed with po-
tent inhibition at μM concentrations. Two of these antiviral peptides
correspond to regions of very high WWIHS score and overlap with
liposome-active peptides (Fig. 10). The two other active peptides have
small, positive WWIHS scores. The same peptides were not active
against pseudotype viruses corresponding to murine leukemia virus
and vesicular stomatitis virus. Regarding the overarching hypothesis
of this review, the HCV data provided by Sabahi et al., are revealing.
They directly demonstrate good overlap between predicted membrane
binding, experimentally observed membrane perturbation, and antivi-
ral activity. They also show that the overlap is incomplete, similar to
the roughly 50% correlation between positive WWIHS scores and
entry inhibition in the examples described above. It also agrees with
the observations above that cross species inhibition is frequently ob-
served, but is often incomplete. We conclude from these observations
that while propensity for membrane binding is a major contributor to
peptide entry inhibition, there are other, as yet unknown, factors that
also contribute.
Fig. 10. Discovery of hepatitis C virus peptide entry inhibitors. The three protein fusion protein complex of HCV containing proteins E1, E2 and p7 was analyzed usingWWIHS to identify
putative membrane interacting sequences. The colored segments on the plot were peptides from a complete set of overlapping peptides that affected synthetic membranes (blue) or
inhibited virus in vitro (red) [34]. The latter sequences are shown in the table.
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4.1. Structure-based identiﬁcation of peptide entry inhibitors
Peptides such as enfuvirtide and itsmimics, derived from the C-helix
heptad repeat (CHR) domain of Class I fusion proteins, may be an
example of peptide entry inhibitors that act by sequence speciﬁc inter-
actionswith fusion proteins. In addition to enfuvirtide (WWIHS=−4.5;
iHHM= 5.5 at pH 7) and the closely related DP178 (WWIHS =−7.0;
iHHM= 7.7), there are other peptide entry inhibitors for HIV that are
derived from the CHR domain of gp41. One such peptide, called C34
[48,52] (WWIHS =−9.6; iHHM= 9.7) inhibits the entry of HIV into
cells with IC50 values in the low μM range in vitro [49]. C34 and
enfuvirtide have overlapping sequences, yet C34 reportedly has a se-
quence that enables it to interact speciﬁcally with a pocket in gp41,
thereby preventing the conformational change required for fusion
[48,52].
In another study, He et al. [98] began with a peptide from the
CHR region of gp41 that partially overlaps with enfuvirtide and C34,
and subsequently engineered the sequence to be a more ideal amphi-
pathic helix, assuming that this would improve pharmacological
properties. In vitro, the peptide they designed, a 32-mer called CP32M,
(WWIHS =−8.7; iHHM= 14.4 at pH 7), is a very potent entry inhib-
itor against many strains of HIV, including enfuvirtide-resistant strains
[98,99], with IC50 values ranging from nM to pM. CP32M interacts
with a protein construct comprised of the NHR sequences of gp41 to
form a 6-helix bundle that mimics the native, post fusion 6-helix bun-
dle. Like enfuvirtide and DP178 [48,52], CP32M was shown to function
by inhibition of fusion. Later, both CP32M and the shorter variants
were shown by X-ray crystallography to interact with a protein con-
struct containing the core three helix bundle of the N-terminal heptad
repeat sequences of gp41. The inhibitors are helical and lie with their
hydrophobic face in the hydrophobic groove between the NHR helices
[99,100], just as the CHR helices interact in the post fusion 6-helix bun-
dle of native gp41.In an additional study [100], the same authors designed overlapping
19–22 residue variants of CP32M (WWIHS−8 to−9, iHHM +15 to
+14) that were shown to have nM IC50 values against all strains of
HIV tested. While the WWIHS score for these peptides is negative at
neutral pH, their interfacial helical hydrophobicmoments are extremely
large because the authors made sequence changes intended to create
essentially ideal amphipathic helices. Thus, these peptides have a pro-
pensity to bind membranes and any other hydrophobic surface by fold-
ing intoα-helices. In the context of the central hypothesis of this review,
this study may be revealing. Some of the engineered sequences are
highly active against multiple strains of HIV, yet bear little sequence
resemblance to the native sequence of gp41. Compared to CP32M,
the active sequences have more than half of their residues changed
with dramatically non-conservative substitutions including M→ E,
I→ K, L→ K, K→ E, I→ E, E→ I and E→ K. One of these sequences
was shown to fold into a 6-helix bundle with the NHR sequence of
gp41, despite having few native residues in the protein–protein inter-
face, suggesting that the interaction is driven mostly by the alignment
of the hydrophobic surface of the amphipathic helixwith the hydropho-
bic groove of the NHR bundle, instead of highly sequence-speciﬁc
interactions.
Following the early success of enfuvirtide and related peptides
against HIV, the same structure-based approach was used to identify
entry inhibitors against other enveloped viruses with Class I fusion
proteins. For example Rapaport et al. [101] described an inhibitory
CHR peptide from the fusion protein of sendai virus. Similarly, Lambert
et al. [102] tested enfuvirtide-like CHR sequences from respiratory syn-
cytial virus, parainﬂuenza virus and measles virus, reporting species-
speciﬁc inhibition of all three in vitro at sub μM concentrations. Lamb
et al. [103] reported that CHR peptides from human T-lymphocyte leu-
kemia virus and bovine leukemia virus inhibit virus entry in a species
speciﬁcmanner. Upon the discovery and identiﬁcation of the SARS coro-
navirus in 2003, several groups [33,71] identiﬁed CHR-based peptide
entry inhibitors from the SARS Class I fusion protein, S2, using the
enfuvirtide/gp41 system as a model. Similarly the discovery of the
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tors based on the C-helix heptad repeat sequences of the MERS S2 pro-
tein [104]. These authors showed by X-ray crystallography that these
peptide inhibitors of MERS co-crystallized as a 6-helix bundle when
mixed with a construct containing the N-terminal helical heptad repeat
core [104].
The available data suggests that these various CHR-derived peptides
may inhibit virus entry by hydrophobic intermolecular interactions
with the hydrophobic grooves in the NHR segments of the Class I fusion
proteins. Whether sequence speciﬁc, native like interactions are essen-
tial for activity is not certain. In any case, this interaction, which may
occur only with transient intermediate structures, is likely to interfere
with the structure and function of the fusion protein during the critical
events of fusion. While some CHR entry inhibitors bind stably and spe-
ciﬁcally to partial gp41 NHR sequences [10], others apparently do not.
Despite evidence that these CHR peptides may act by sequence speciﬁc
interactions, they have one universal feature in common that makes
them similar to the other membrane interacting sequences described
elsewhere in this review. They are highly amphipathic, with iHHM
values between 5 and 15 kcal/mol. This property arises from the fact
that, in the native structure, they pack into a very hydrophobic groove
in the NHR three helix core that is present in all Class I fusion proteins.
Peptides with very large iHHM scores are likely to fold into α-helices
and interact with any available hydrophobic surface. Enfuvirtide ana-
logs interact with membranes, thus supporting this hypothesis [48].
The idea thatmembrane bindingmay be important is also strengthened
by the observation that an inactive enfuvirtide variant with several hy-
drophobic residues removed from the C-terminus can have its activity
restored by the C-terminal addition of an octyl chain [100].
Porotto and colleagues [105] tested a set of “leash” domain peptides
from inﬂuenza for inhibition. The inﬂuenza HAhelical bundle contains a
linear, non-helical sequence that is similar to the CHR sequences of
other Class I fusion proteins in that they pack into grooves in the core
N-helix bundle. Unmodiﬁed leash domain peptides, including the lon-
gest and most hydrophobic variant GTYDHDVYRDEALNNRFQIKGV
ELKSGYKDW (WWIHS= 2.1; iHHM=4.7) were inactive against inﬂu-
enza virus in vitro. These authors then attached cholesterol to the amino
termini of the leash peptides. This modiﬁcation by a very hydrophobic
cholesterol will effectively tether the peptide to the membrane.
Cholesterol-modiﬁed leash peptideswere found to be potent inhibitors,
with EC50 values as low as 0.4 μM. These authors showed that entry in-
hibition is due to inhibition of fusion, and that multiple strains of inﬂu-
enza virus can be inhibited by cholesterol-conjugated leash peptides.
They postulated that cholesterol conjugation insures that the peptide
becomes co-encapsulated in the endosome with the virus and can act
on the fusion protein when the pH decreases.
4.2. Accidental identiﬁcation of peptide entry inhibitors
Ourmain hypothesis is also supported bymultiple published reports
of other peptides that are entry inhibitors of enveloped viruses. For
example, Brandt and colleagues have described the accidental discovery
of a peptide with broad-spectrum antiviral activity. This peptide, called
EB, was based on a signal sequence, and was initially designed to facili-
tate cellular entry of an inhibitor of herpes simplex virus [28]. However
the “carrier” peptide, EB, was found to be a potent virus inhibitor in pure
form. This peptide has an N-terminal solubility sequence, RRKK
followed by a hydrophobic, uncharged 16 residue sequence,
AAVALLPAVLLALLAP, (WWIHS = 3.5) that has a propensity for mem-
brane interaction. EB inhibits numerous unrelated viruses, including
herpes simplex virus [28], inﬂuenza virus [106] and vaccinia (small
pox) virus [107], consistentwith inhibition that is dependent on peptide
physical chemistry, rather than on sequence-speciﬁc interactions with
viral fusion proteins. Inhibition of viral entry by EB occurs at an early
stage, likely by inhibition of fusion [108,109]. Brandt and colleagues
showed that EB pre-incubation protected cells from virus, showingthat the peptide binds to, or enters, cells [108,109]. They also showed
that EB causes aggregation of both viruses and various proteins, driven
by the hydrophobic C-terminal tail of the peptide [108,109].
In a remarkably similar narrative, Nicol et al. [110] describe the acci-
dental discovery of a very similar peptide with anti-inﬂuenza activity.
This 12-residue peptide was being studied for its anti-inﬂammatory
properties, but was found to have direct antiviral activity. The initial se-
quence (called FluPep), WLVFFVIFYFFR (WWIHS = 10.5) is an ex-
tremely hydrophobic 12-residue peptide, with physical properties that
are very similar to the 16 hydrophobes of EB described in the previous
paragraph. The authors increased the apparent solubility of FluPep by
adding the same four N-terminal basic residues (RRKK) as found in
the peptide EB (above), yielding a peptide they called FluPep4. FluPep4
has IC50 values for inhibition of various inﬂuenza viruses in vitro
between 135 nM and 30 pM [110]. The authors showed that FluPep4
inhibits virus binding to cells through a direct physical interaction
with the virus. Because of its extreme hydrophobicity, FluPep4 will
likely interact very strongly with itself and with all cellular and viral
membranes.
Graham and colleagues have also reported the accidental discovery
of a potent antiviral peptide. Initial information from a yeast 2-hybrid
analysis indicated that the fusion protein of respiratory syncytial virus
(RSV) could interact with RhoA, a small intracellular GTPase [111]. Fol-
lowing this discovery, the authors identiﬁed the linear peptide sequence
of RhoA responsible for the interaction, ILMCFSIDSPDSLEN (WWIHS =
4.4). While a physiologically relevant interaction between the fusion
protein of RSV and RhoA seemed unlikely, the peptide was nonetheless
found to inhibit RSV infection in vitro [21]. The same peptide also in-
hibits HIV [21]. Subsequent investigation conﬁrmed that viral inhibition
was unrelated to any putative interaction with RhoA. Instead the RhoA-
derived peptides, which are hydrophobic, interact directly with the
virus, and by doing so block cellular binding and entry. In agreement
with the hypothesis we are exploring in this review, these authors con-
cluded that “the antiviral activity of RhoA-derived peptides is… a function
of the peptides' ‘intrinsic biophysical properties’” and that “the combination
of hydrophobicity and negative charge appears to be an effective pattern for
many antiviral molecules that target RSV as well as many other enveloped
viruses” [21].
4.3. Brute force approaches to the identiﬁcation of peptide entry inhibitors
Akkarawongsa et al. generated a comprehensive set of overlapping
15-residue peptides representing the entire surface exposed portion of
gB-1, the Class III fusion protein of herpes simplex virus [80]. When
thewhole setwas tested for antiviral activity, sevenpeptideswere iden-
tiﬁed that inhibit HSV. Three of the peptides were not tested further be-
cause theywere insoluble (a common problem for the antiviral peptides
discussed throughout this review). The three most active peptides had
IC50 values less than 20 μM, in vitro. In Fig. 11, we show the structure
and WWIHS score of the gB-1 protein with the positions of the seven
inhibitory peptides in red. In very strong support of our overarching hy-
pothesis that membrane interface binding peptides can broadly inhibit
viral entry, most of the seven antiviral peptides identiﬁed by this non-
biased, brute force approach overlap with peaks of positive WWIHS
score in the C-terminal portion of the fusion protein. There were also
several positive WWIHS segments that did not show activity, a result
that is consistent with the success rate reported above for intentionally
identifying antiviral peptides using WWIHS. Thus, the efﬁciency of the
approach described earlier of identifying candidates based on WWIHS
and then testing the small number of candidates directly for activity is
further validated by this work. The authors systematically measured,
for each soluble antiviral peptide, direct viral inactivation, inhibition of
cell binding, inhibition of entry, and host cell protection. They found
that the peptides act mostly through entry inhibition, with a small con-
tribution of direct viral inactivation and host cell protection. No inhibi-
tion of cell binding was observed.
Fig. 11.WWIHS analysis of the putative fusion protein Gb of herpes simplex virus compared with inhibitory peptides identiﬁed by Akkarawongsa et al. [80] using a brute force approach
based on in vitro testing of a comprehensive set of overlapping peptides from the Gb protein. A partial monomeric structure of Gb [PDB ID: 3NWF] is shown with the active sequences in
color. The peptides tested are shown in the table. Those with no EC50 value were not tested due to insolubility.
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ping 18 residue peptides against the entire polyprotein of hepatitis C
virus. They identiﬁed 11 peptides with signiﬁcant antiviral activity,
many of which have positiveWWIHS scores. The most active inhibitory
peptide, called C5A, is very hydrophobic and has a strong membrane
binding propensity. It is an amphipathic helix from the membrane an-
chor domain of the nonstructural protein NS5A. C5A, SWLRDIWDWI
CEVLSDFK, (WWIHS = 9.0, iHHM = 5.2) interacts directly with the
hepatitis C viral envelope and is virolytic with EC50≤ 1 μM. It blocks in-
fection most actively if incubated with virus during/prior to the initial
entry stage. Interestingly, C5A also eliminated virus in chronically in-
fected cells, suggesting that it can enter cells. C5A made from L-amino
acids and C5A made from D-amino acids had the same biological activi-
ty [112]. In a separate study C5Awas shown to also have potent activity
against HIV, and its activity was shown to be due to direct disruption of
the viral envelope integrity [112]. In this study also, C5A was able to
inhibit an already established HIV infection in vitro. However C5A
does not inhibit vesicular stomatitis virus, nor does it inhibit a non-
enveloped adenovirus. A less amphipathic but equally hydrophobic var-
iant of C5A with two pairs of amino acids swapped in position is not
active against HCV or HIV. C5A permeabilized lipid vesicles with high
potency like a lytic toxin, which is consistent with its high WWIHS
score and high amphipathicity. However, unlike non-speciﬁc lytic pep-
tides (e.g. melittin from bee venom [113]) C5A does not disrupt cellular
membranes and is not toxic against living mammalian cells at low con-
centration [112].
The hydrophobicity, secondary structure, helical hydrophobic
moment and mechanism of action of C5A are all very similar to the
stem-derived, dengue peptide, DN59, described above. Importantly,
the D-amino acid enantiomer of C5A has the same activity as the L-
enantiomer, showing that sequence speciﬁc peptide–protein interac-
tions are not involved in antiviral activity. Li et al. [112] made a series
of C5A variants with altered hydrophobicity and helicity. The anti HCV
and anti-HIV activities of these variants in vitro were remarkably simi-
lar. Of the 14 variants studied against the two viruses, at least 9 had
IC50 values between 0.5 and 5 μM, demonstrating, again, that entryinhibition is not a highly sequence dependent activity and that se-
quence changes donot abrogate antiviral activity if they do not diminish
interfacial hydrophobicity or amphipathicity. Only variants of C5A with
nonpolar to polar changes were inactive.
In an approach very similar to the discovery of C5A, Si et al. [114]
tested all overlapping 18 aminoacid peptides from four proteins thought
to be important in the entry of hepatitis C virus: CD81, scavenger recep-
tor B1, claudin 1 and occludin. They tested 113 peptides. Two overlap-
ping peptides from claudin 1 were very potent inhibitors of HCV.
These peptides, called CL-58 (MANAGLQLLGFILAFLGW, WWIHS = 8.1;
iHHM = 2.5) and CL-59 (AFLGWIGAIVSTALPQWR, WWIHS = 6.0;
iHHM = 4.3) are uncharged, very hydrophobic and amphipathic se-
quences. In fact, these sequences are part of the ﬁrst membrane span-
ning α-helix in the claudin-1 protein, and thus are presumably buried
in the membrane and not accessible to the virus during entry. These in-
hibitory sequences block HCV pseudovirus entry and whole virus entry
with EC50 around 1–3 μM. They also suppress establishedHCV infections
in cell culture. Inhibition of entry does not occur at the binding step, and
the effect of peptide can be removed by washing the virus or the cells. A
large number of translation and truncation variants were tested. More
than half had similar activity to CL-58 andCL-59.While a scrambledpep-
tide is mostly inactive, the D-amino acid CL-58 peptide is fully active,
suggesting that sequence speciﬁc intermolecular interactions are not in-
volved in the entry inhibition.
Bai et al. used phage display to identify three peptides that adhere
to the West Nile virus fusion protein E [115]. Two of the three peptides
that bound strongly to the fusion protein did not inhibit virus in vitro.
However, one peptide, which the authors called p1, inhibited West
Nile virus in vitro with IC50 = 67 μM. Peptide p1, DTRACDVIALLCH
LNT, (WWIHS = 1.9) is more hydrophobic than the two inactive
sequences and has a small, but positive WWIHS score. A series of trun-
cation and insertion peptides were tested to ﬁnd sequences with in-
creased activity. The most hydrophobic of the variants tested, CDVIAL
LACHLNT, (WWIHS= 3.0), called P9,was also themost potent inhibitor
of West Nile virus, with IC50 = 2.6 μM. The authors also tested the pep-
tides against the related dengue virus, which has a fusion protein that is
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the opposite relative activities of P1 and P9 were found: P1 was highly
active while P9 was not active. Finally, the authors showed that P9
inhibitedWest Nile virus in amousemodelwith brain involvement, de-
creasing viral loads and increasing survival dramatically [115]. Remark-
ably, the peptide P9was apparently able to cross the blood brain barrier,
an important property for therapeutics intended to treat viruses that
replicate in the brain.
Reil and colleagues [116,117] hypothesized that the long recognized
inhibition of HIV in patients co-infected with the common, asymptom-
atic GB virus C, which is related to hepatitis C, was due to a direct inter-
action between the surface glycoprotein E2 of the GB virus C and gp41,
the Class I fusion protein of HIV. These authors examined peptides from
the E2 protein and identiﬁed two overlapping E2 peptides, WDRGNV
TLLCDCPNGPWVWV, (WWIHS = 6.5, iHHM = 3.5) and LCDCPNGP
WVWVPAFCQAVG (WWIHS = 5.4, iHHM = 2.9) that inhibit HIV
in vitro. These peptides are rich in aromatic residues and are both
hydrophobic and amphipathic, giving them a strong propensity for
membrane interaction. They inhibit HIV in cell culture with IC50 values
of 2 and 0.2 μM, respectively. The authors showed that the two peptides
inhibited HIV entry, and do so at an early step, but one that occurs after
cell-surface binding, probably fusion. They also showed that this effect is
due to an interaction with the HIV gp41 fusion protein that alters its
conformational rearrangement, and may prevent the formation of the
6-helix bundle needed for fusion. These authors concluded that the E2
peptides speciﬁcally bind at the gp41–gp120 interface based on com-
petitive binding assays and weak sequence similarity between the E2
peptides and HIV gp41. Based on the fact the physical chemistry of the
E2 peptides is very similar to themany peptides discussed here, we hy-
pothesize that their mechanism of action may include non-sequence
speciﬁc interactions between the peptides and the hydrophobic sur-
faces of the fusion protein–membrane complex.
4.4. Entry inhibition by membrane-permeabilizing, cationic antimicrobial
peptides
Cationic antimicrobial peptides constitute a collection of more
than 1000 known peptides that are extraordinarily diverse in sec-
ondary and tertiary structure, but have similar antibacterial and anti-
fungal activities. AMPs are found in all classes of life and are a critical
part of the innate immune systems of vertebrates and invertebrates
[118–120]. Most vertebrates, including humans, produce many differ-
ent AMPs that have broad spectrum activity against many types of bac-
teria and unicellular fungi. The activity of AMPs against bacteria has
been studied intensively since their discovery in the 1980s [121,122].
While there are some variations, a unifying mechanism of antibacterial
action has emerged from many studies [118,123]: AMPs preferentially
bind to the anionic plasma membranes of bacteria (both Gram positive
and Gram negative) and, by virtue of their interfacial activity [123], dis-
rupt the organization and continuity of bacterial membranes. The de-
gree of membrane disruption increases sequentially [124–126] from
loss of transmembrane potential within seconds, to leakage of small
molecules, leakage of macromolecules and ﬁnally destruction of overall
cellular architecture. The membrane disrupting nature of AMPs arises
from the fact that they are amphipathic, with polar and hydrophobic
surfaces, but that the hydrophobic surfaces are interrupted by polar/
cationic residues. We have described how their “interfacial activity” is
dependent on “imperfect amphipathicity” [123].
Antiviral activity has been observed, in vitro, for multiple AMPs and
it has been proposed that they have evolved to have antiviral activity as
well as antibacterial activity. For example, LL37 is a 37-residue cationic,
amphipathic helical AMP that is released from neutrophil granules and
epithelial cells and that has broad-spectrum activity against many bac-
teria and pathogenic fungi. Recent reports [127] have shown that LL37
also has broad-spectrum activity against inﬂuenza A viruses, in vitro,
by a mechanism that is consistent with entry inhibition. The IC50 ofLL37 is in the low μM range. LL37-dependent inhibition of virus-cell
binding was not observed. Instead, like the anti-dengue peptide DN59
discussed above, LL37 caused a direct physical disruption of the viral
membrane [127]. LL37 does not have a favorableWWIHS score, overall,
but interacts with membranes because it folds into an α-helix with a
very hydrophobic face. The interfacial helical hydrophobic moment,
iHHM, of LL37 is 14.2 at neutral pH, which is an extremely high value
(see Table 1).
Similarly, multiple classes of defensins, which are cyclic and/or
disulﬁde-crosslinked cationic/hydrophobic peptides, have also been
shown to have anti-viral activity against HIV [128], herpes simplex
virus [129], inﬂuenza A virus [130,131], and the SARS coronavirus
[132]. Inhibition has been reported to arise from peptide-induced viral
aggregation and direct virolytic effects. Doss et al. [131] reported a
study of a collection of synthetic theta defensin variants (cyclic 18-
residue β-sheet rich neutrophil peptides) from which they identiﬁed
several sequences with IC50 values against inﬂuenza virus that are less
than 1 μM. Entry inhibition by theta defensins required that the
peptide–virus interaction occur before cell binding and was a result of
direct peptide–virus interaction; the theta defensins apparently drive
large-scale aggregation of viral particles [131].
5. A shared mechanism of action for peptide entry inhibitors?
In 2013 Kumar and colleagues published the “Antiviral PeptideData-
base” [133] which describes more than 600 antiviral peptides covering
all possible mechanisms of action. A signiﬁcant proportion of those an-
tiviral peptides are entry inhibitors, the class we have discussed in this
review.Most of the peptide entry inhibitors described here were initial-
ly expected to inhibit viral entry by providing sequence-speciﬁc com-
petitive inhibition of intermolecular interactions, mostly involving the
viral fusion proteins. However, in the many studies we examined,
there is little evidence of highly sequence speciﬁc interactions, other
than the evidence provided by some Class I, CHR-derived peptides
mimicking enfuvirtide. Instead there is strong evidence of generic activ-
ity for most peptide entry inhibitors. Peptides that were tested against
other enveloped viruses often show at least some cross-species inhibi-
tion, even against unrelated viruses. The D-enantiomers show activity,
when tested, as do some truncations, insertions and other sequence
variations. Yet, even without blocking speciﬁc protein–protein interac-
tions, these many peptides effectively inhibit virus entry into cells
in vitro with EC50 values from sub nM to low μM. In the few cases re-
ported, inhibition also occurs in vivo.
The mechanisms of action of these peptide entry inhibitors have
been studied in multiple laboratories. Some of the peptides have direct
physical effects on the virus particles, causing either physical disruption
of the lipid bilayer of the viral envelope (virolysis) or causing virus
aggregation. Some have been shown to bind to and affect synthetic
membranes. Some inhibitory peptides are reported to inhibit binding
of viruses to cells, which has been attributed to direct peptide interac-
tions with the virus particles. Other peptides seem to act at the level
of membrane fusion, inhibiting fusion of bound virus to cells. In at
least one case, fusion inhibition was due to premature initiation of the
fusion protein conformation after peptide binding to the viral envelope
membrane. Some peptide entry inhibitors bind directly to cells and in-
terfere with virus binding and/or fusion at the cell surface, which may
occur only after endocytosis of bound peptide and virus. Many studies
suggest that multiple mechanisms are at play simultaneously.
Here we hypothesize that peptides with a propensity for membrane
binding, due to interfacial hydrophobicity or amphipathicity, can interfere
with enveloped virus entry by direct physical interaction with the hydro-
phobic surfaces, on both membranes and fusion proteins, that are critical
for fusion and entry. In other words, the peptide entry inhibitors
discussed here share overlappingmechanisms of action that are derived
from their shared physical chemistry as follows: Essentially all the
peptide entry inhibitors that we identiﬁed are at least somewhat
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membrane interfaces and other hydrophobic surfaces. Many of them
are very hydrophobic and/or highly amphipathic. Furthermore, many
of them have acidic isoelectric points so that the low pH environment
of late endosomes, where most viral cell fusion takes place, will trigger
loss of charge and increased membrane binding. Except for anti-HIV
peptides (because HIV fusion takes place at neutral pH) the WWIHS
scores we report here reﬂect the low pH, membrane-bound state
where aspartate and glutamate are effectively uncharged and histidine
is charged. It is not known, at this time, whether membrane binding
can directly affect viral fusion, or whether interaction with the fusion
protein itself is an absolute requirement for entry inhibition. However
we note, as did Rapaport et al. 20 years ago [101], that membrane bind-
ing of an inhibitory peptidewill greatly increase the effective concentra-
tion of the peptide in the vicinity of the fusion protein thus interaction
with membrane and interaction with the fusion protein may be effec-
tively coupled.
Furthermore, we propose that each fusion protein–membrane com-
plex exposes hydrophobic surfaces with somewhat variable detailed
physical characteristics. These characteristics include the size, shape
and underlying secondary structure of exposed hydrophobic patches,
as well as the nature of the polar or charged residues that are near the
hydrophobic surfaces. Thus, on the one hand similarities across all clas-
ses of fusion proteins give rise to frequent cross-species inhibition by
peptide entry inhibitors. But on the other hand, variation in the physical
details of the exposed hydrophobic surfaces causes some peptide entry
inhibitors to be inactive against some enveloped viruses.
There may also be indirect ways in which interfacial binding pep-
tides can affect viral entry. For example, the spike proteins of enveloped
viruses are very crowded in the viralmembrane (see Fig. 1) andmay in-
teract laterally, leading to the proposal that the conformational change
that drives fusion is a cooperative event involving all of the spikes in a
virus particle nearly simultaneously. If this is true, then cooperativity re-
sults from lateral interactions between proteins, perhaps including the
TMdomains. Thus,membrane physical properties could be critically im-
portant to the events that drive viral entry and it should be possible for
peptides to interferewith the function of viral fusion proteins by chang-
ing the physical chemistry of the membrane itself by direct interaction.
Evidence for this mechanism was discussed above for several peptide
entry inhibitors.
Finally we note here the similarity in physical chemistry between
membrane partitioning peptides and membrane translocating peptides
[134]. Hydrophobic peptides that partition into membranes should
also be able to cross cell membranes and enter cells. They may also
cross endothelial layers in vivo, perhaps even including the blood
brain barrier [115]. Thus peptides that function as entry inhibitors
against viruses in vitro by the mechanism we propose here may inher-
ently also have promising bioavailability characteristics in vivo due to
membrane binding and translocation. This idea is supported by the
very long half time of enfuvirtide in humans (tens of hours) compared
to most peptides (minutes). In support of this possibility, we have
showndirectly that somepeptide entry inhibitors can translocate across
plasma membranes and enter cells (H. Badani and W.C. Wimley, not
shown).
6. Implications and future directions
Effective therapeutics against enveloped viruses are rare. While a
few drugs have been developed against HIV, inﬂuenza virus, and a few
other viruses, these drugs are not ideal, and viruses often become resis-
tant. For most enveloped viruses, there are no effective therapies. Thus
entry inhibition represents an attractive and underutilized target in
the search for new therapeutics. The hypothesis we have described
here, that peptide entry inhibitors act by physical chemical interaction
with hydrophobic surfaces exposed during fusion, suggests a novel
approach to the discovery of entry inhibitors, one that focuses on thephysical chemistry of putative entry inhibitors. Instead of the mostly
brute force, structure based or accidental discovery in the literature to
date, we propose that an intentional search for novel hydrophobic/
amphipathic peptide entry inhibitors based on their physical chemistry,
with an orthogonal selection for other critical properties such as solubil-
ity and pH sensitivity, could result in highly optimized and clinically ef-
fective peptide inhibitors of viral entry. Furthermore, since native-like,
speciﬁc intermolecular interactions are probably not important, entry
inhibitors can be made using protease resistant non-natural or D-
amino acid peptides, using peptide mimetics such as peptide-nucleic
acids or beta-peptides, or using polymers unrelated to peptides.
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